Derek Chalmers, Cara Therapeutics CEO
October 20, 2020 01:00 AM EDTUpdated 06:34 AM
Deals
FDA+

Cara lines up a $440M deal for US rights to its late-stage drug for se­vere itch, with $150M cash on the ta­ble

Nicole DeFeudis

Editor

With plans afoot to file an NDA for what could be its first ap­proved drug, Cara Ther­a­peu­tics is piv­ot­ing its fo­cus to com­mer­cial­iza­tion. And Swiss …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Sanofi, Ope­nAI, For­ma­tion Bio de­but pa­tient re­cruit­ing tool, will use in Phase 3 mul­ti­ple scle­ro­sis stud­ies

Maze's ALS spin­out Trace Neu­ro­science rais­es $101M for ALS and neu­ro work

Up­dat­ed: As­traZeneca, Dai­ichi Sankyo re­place lung can­cer fil­ing for En­her­tu suc­ces­sor

No­var­tis pays $150M up­front to Schrödinger in new drug deal, ramps up soft­ware use

Roche teams with Flare Ther­a­peu­tics on tran­scrip­tion fac­tors

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times